Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
Claire Wainwright(Royal Children's Hospital), Michael Boyle(McMaster University), Bonnie W. Ramsey(Seattle Children's Hospital), Michael W. Konstan(Case Western Reserve University), Félix Ratjen(Hospital for Sick Children), Marco Cipolli(Azienda Ospedaliera Universitaria Integrata Verona), J.S. Elborn(Royal Brompton Hospital), Karen McCoy(Nationwide Children's Hospital), À. Munck(Université Paris Cité), Jane C. Davies(Guy's and St Thomas' NHS Foundation Trust), K. De Boeck(University Medical Center Utrecht), Gautham Marigowda(Westmead Institute for Medical Research), Susanna A. McColley(Northwestern University), Carla Colombo(IRCCS Istituto Auxologico Italiano), Xiaohong Huang(Vertex Pharmaceuticals (United States)), David Waltz(Vertex Pharmaceuticals (United States)), Steven M. Rowe(University of Alabama at Birmingham), Edward F. McKone(University College Dublin), Patrick A. Flume(Medical University of South Carolina)
Cited by 1,620
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System
|Medical Care|2002|1.3k
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1999|1.3k